{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=IDH+Wildtype+Recurrent+Glioblastoma",
    "query": {
      "condition": "IDH Wildtype Recurrent Glioblastoma"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 30,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=IDH+Wildtype+Recurrent+Glioblastoma&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-25T13:45:04.027Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07386002",
      "title": "The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype"
      ],
      "interventions": [
        {
          "name": "Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "T-MAXIMUM Pharmaceutical Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 40,
      "start_date": "2026-06-30",
      "completion_date": "2029-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-10",
      "last_synced_at": "2026-06-25T13:45:04.027Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07386002"
    },
    {
      "nct_id": "NCT07416188",
      "title": "Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Glioblastoma",
        "Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype",
        "Relapsed Cancer",
        "Recurrent Tumor",
        "Glioblastoma Multiforme",
        "Recurring Glioblastoma",
        "Brain and Central Nervous System Tumors",
        "Glioma",
        "Glioblastomas",
        "Grade IV Astrocytoma",
        "GBM",
        "Recurrent Glioma (Glioblastoma Multiforme)",
        "High Grade Glioma",
        "Glioma, Malignant",
        "Brain Cancer"
      ],
      "interventions": [
        {
          "name": "LMP744",
          "type": "DRUG"
        },
        {
          "name": "Conventional Surgery or Biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 40,
      "start_date": "2026-06-30",
      "completion_date": "2032-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-25",
      "last_synced_at": "2026-06-25T13:45:04.027Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07416188"
    },
    {
      "nct_id": "NCT07089641",
      "title": "ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "IDH Wildtype Glioblastoma",
        "Recurrent Astrocytoma",
        "IDH Wildtype Recurrent Glioblastoma",
        "Resectable Astrocytoma",
        "Resectable Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "EGFR Inhibitor ERAS-801",
          "type": "DRUG"
        },
        {
          "name": "Fludeoxyglucose F-18",
          "type": "OTHER"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Surgical Procedure",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2025-07-28",
      "completion_date": "2028-07-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-07",
      "last_synced_at": "2026-06-25T13:45:04.027Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07089641"
    },
    {
      "nct_id": "NCT06273176",
      "title": "The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Glioblastoma, IDH-wildtype",
        "Glioblastoma",
        "Glioblastoma Multiforme of Brain",
        "Astrocytoma, Malignant",
        "Brain Neoplasms",
        "Brain Neoplasms, Adult, Malignant",
        "Brain Neoplasms, Adult",
        "Recurrent Adult Brain Tumor",
        "Recurrent Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Awake mapping under local anesthesia",
          "type": "PROCEDURE"
        },
        {
          "name": "Asleep mapping under general anesthesia",
          "type": "PROCEDURE"
        },
        {
          "name": "Resection under general anesthesia without mapping",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Erasmus Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "Up to 90 Years"
      },
      "enrollment_count": 225,
      "start_date": "2023-01-01",
      "completion_date": "2028-01-01",
      "has_results": false,
      "last_update_posted_date": "2024-02-22",
      "last_synced_at": "2026-06-25T13:45:04.027Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Boston, Massachusetts",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06273176"
    },
    {
      "nct_id": "NCT06552260",
      "title": "A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Glioblastoma",
        "Recurrent Glioblastoma",
        "Brain Tumor"
      ],
      "interventions": [
        {
          "name": "Troriluzole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ugonma Chukwueke",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2025-02-19",
      "completion_date": "2027-08-01",
      "has_results": false,
      "last_update_posted_date": "2025-09-11",
      "last_synced_at": "2026-06-25T13:45:04.027Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06552260"
    },
    {
      "nct_id": "NCT05465954",
      "title": "Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "High Grade Astrocytic Tumor",
        "Recurrent Glioblastoma, IDH-Wildtype",
        "Recurrent Gliosarcoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Efineptakin alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2023-01-24",
      "completion_date": "2028-10-15",
      "has_results": false,
      "last_update_posted_date": "2026-01-12",
      "last_synced_at": "2026-06-25T13:45:04.027Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05465954"
    },
    {
      "nct_id": "NCT04910022",
      "title": "Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma",
        "Diffuse Glioma"
      ],
      "interventions": [
        {
          "name": "NMS-03305293",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nerviano Medical Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2021-12-01",
      "completion_date": "2027-09-07",
      "has_results": false,
      "last_update_posted_date": "2025-08-19",
      "last_synced_at": "2026-06-25T13:45:04.027Z",
      "location_count": 11,
      "location_summary": "Phoenix, Arizona • Orange, California • Jacksonville, Florida + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04910022"
    },
    {
      "nct_id": "NCT06410248",
      "title": "Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Glioblastoma, IDH-Wildtype",
        "Recurrent WHO Grade 2 Glioma",
        "Recurrent WHO Grade 3 Glioma",
        "Recurrent WHO Grade 4 Glioma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Resection",
          "type": "PROCEDURE"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Triapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2024-07-23",
      "completion_date": "2030-05-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-06-25T13:45:04.027Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06410248"
    },
    {
      "nct_id": "NCT07349693",
      "title": "Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Recurrent Glioblastoma, IDH-Wildtype"
      ],
      "interventions": [
        {
          "name": "Cerebraca wafer",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide (for relapsed malignant glioma)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Everfront Biotech Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 175,
      "start_date": "2026-11-01",
      "completion_date": "2030-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-20",
      "last_synced_at": "2026-06-25T13:45:04.027Z",
      "location_count": 1,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07349693"
    },
    {
      "nct_id": "NCT05789394",
      "title": "Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Glioblastoma, IDH-Wildtype",
        "Recurrent Astrocytoma, IDH-Mutant, Grade 4",
        "Astrocytoma, Grade IV"
      ],
      "interventions": [
        {
          "name": "Allogeneic Adipose-derived Mesenchymal Stem Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Craniotomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Ommaya Reservoir Tap",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2023-06-16",
      "completion_date": "2027-07-24",
      "has_results": false,
      "last_update_posted_date": "2026-04-02",
      "last_synced_at": "2026-06-25T13:45:04.027Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05789394"
    }
  ]
}